Clinical Trial Update: A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions [Phase 2]

View source ↗

Summary

Phase 2 trial update for lorlatinib in advanced ALK/ROS1-rearranged NSCLC with CNS metastasis and no measurable extracranial lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: UNKNOWN